Ironwood Pharmaceuticals Files for IPO (Cambridge, MA)
Ironwood Pharmaceuticals announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its Class A common stock. The price range and number of shares to be offered has yet to be determined.

Telegent files for $250 Million IPO with the Securities and Exchange Commission (Sunnyvale, CA)
The IPO markets are beginning to thaw again, as Telegent has filed for a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common shares for $250 million. Telegent provides single-chip solutions that enable live television streaming on mobile devices, laptops, and other portable gadgets.

Joseph Pynadath Joins Digital Fuel as New VP of Sales (San Mateo, CA)
Digital Fuel has recruited Joseph Pynadath as its Vice President of Sales, North America. Pynadath has 16 years of experience in the enterprise and software as a service (SaaS) segment and will take steps accommodate the sizable and growing sales momentum for the company’s IT Cost Management and Service Level Management products in the U.S. and Canada.

2Wire Wins Light Reading Top Picks Award (San Jose, CA)
Light Reading, the leading online media, research, and focused event company, has chosen the 2Wire HomePortal® GEM™ platform as the winner of the Fixed Access category in the first annual Light Reading Top Picks Award. The decision comes after weeks of discussions with readers, analysts, and industry sources. The program awards communications products and services from across the world for their potential to shake up the industry.

Celladon and the University of Minnesota Create Technology to Develop Heart Failure Treatments (La J
Research conducted by the University of Minnesota in collaboration with Celladon Corporation has led to the invention of technology that more rapidly identifies compounds for the treatment of heart failure. The technology was developed by the university’s Dr. David Thomas and Dr. Razvan Cornea and Celladon Corporation’s Dr. Krisztina Zsebo and allows for increased screening efficiency of compounds capable of disrupting the interactions of proteins implicated in the development of heart failure.